Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Sun, 03/26/23 - 03:36 pm
Tags:
PTC Therapeutics, Novartis, Zolgensma, SMA, Novo Nordisk, Ozempic, obesity, diabetes, Baxter, M&A, Celltrio, Thermo Fisher, Pfizer, Astellas, Xtandi, NIH
Novartis pulls the plug on UK-based cardiovascular study
Endpoints
Wed, 03/22/23 - 09:11 pm
Tags:
Novartis, clinical trials, Leqvio, UK, Cardiovascular
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Fierce Biotech
Wed, 03/22/23 - 10:13 am
Tags:
Flare Therapeutics, funding, Pfizer, Eli Lilly, Novartis, transcription factors
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
Wed, 03/22/23 - 10:03 am
Tags:
AACR, Moderna Therapeutics, Allogene, AstraZeneca, Merck, Roche, Novartis, Eli Lilly, Innovent, Springworks, Biogene, Relay Therapeutics, Vivace Therapeutics
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Mon, 03/20/23 - 04:47 pm
Tags:
Novartis, SMA, Zolgensma, gene therapy
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Mon, 03/20/23 - 09:51 am
Tags:
Sangamo Therapeutics, Novartis, Biogen, neurology, gene regulation therapies
Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer
Endpoints
Sun, 03/19/23 - 01:36 pm
Tags:
Novartis, Tafinlar, Mekinist, pediatric, brain cancer, FDA
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Sat, 03/18/23 - 03:37 pm
Tags:
Medtronic, Medtech, inflation, drug pricing, Pfizer, Novartis, Merck, Bristol Myers Squibb, Keytruda, Opdivo, Yervoy, lung cancer, Xiidra, JNJ, executive compensation
Sat, 03/18/23 - 03:34 pm
Tags:
Medtronic, Medtech, inflation, drug pricing, Pfizer, Novartis, Merck, Bristol Myers Squibb, Keytruda, Opdivo, Yervoy, lung cancer, Xiidra, JNJ, executive compensation
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
BioSpace
Wed, 03/15/23 - 11:17 am
Tags:
Mediar Therapeutics, Novartis, Pfizer, fibrosis
After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra
Fierce Pharma
Tue, 03/14/23 - 11:30 am
Tags:
Novartis, Xiidra, ophthalmology
Seeking to boost shareholder returns, Novartis readies new $11B buyback round
Fierce Pharma
Mon, 03/13/23 - 04:42 pm
Tags:
Novartis, share repurchase
Sandoz, betting on biosimilar sales, to build new production plant
BioPharma Dive
Thu, 03/9/23 - 09:15 pm
Tags:
Sandoz, Novartis, drug manufacturing, Slovenia, biosimilars
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Fierce Pharma
Wed, 03/8/23 - 09:51 am
Tags:
Novartis, Pharma CEOs, Vas Narasimhan, executive pay, restructuring
Novartis ready to head for deep space with Voyager after a year 'kicking the tires'
Fierce Biotech
Mon, 03/6/23 - 11:41 am
Tags:
Novartis, Voyager Therapeutics
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Sun, 03/5/23 - 03:09 pm
Tags:
Novartis, Pluvicto, prostate cancer
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
Tags:
NASH, clinical trials, 89Bio, Arrowhead Pharmaceuticals, Can-Fite BioPharma, Ewopharma, Hepagene Therapeutics, JNJ, Ligand Pharmaceuticals, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novartis, Sagimet Biosciences, Terns Pharmaceuticals, Viking Therapeutics
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
Tags:
FDA, Acadia Pharmaceuticals, Apellis Pharmaceuticals, AstraZeneca, Biogen, Biomarin, Cidara Therapeutics, Emergent BioSolutions, GSK, Incyte, Ionis Pharmaceuticals, Melinta Therapeutics, Mundipharma, Novartis, Pfizer, Pharming, Regeneron, Roche, vaccines, RSV, ALS, COVID-19
Fulcrum's clinical hold caps off tough week for sickle cell drug development
Fierce Biotech
Sun, 02/26/23 - 10:20 pm
Tags:
Fulcrum Therapeuticsl, FDA, sickle cell disease, clinical trials, FDX-6058, Novartis, Sangamo, Graphite Bio
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Sun, 02/26/23 - 10:16 pm
Tags:
Novartis, NASH, Pliant Therapeutics, PLN-1474

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.